Private equity firm Quadria Capital has concluded a Rs 475.31 crore investment in biopharmaceutical active ingredient manufacturer Concord Biotech. The transaction has been carried out through Quadria Capital’s Singapore-based SPV, Helix Investments Pte Ltd.
Other investors in the SPV are Rising Tide and Neuberger Berman. Concord is among the leading manufacturers of fermentation-based biopharmaceutical APIs, focused on niche segments such as immunosuppressant, oncology, anti-fungal and anti-bacterial. “We believe that now is the time to take the business to the next level by extending therapy expertise and introducing new range of products. In this pursuit of ours, we are delighted to have a partner like Quadria, who we believe will help us in the next phase of our growth through their domain expertise and global network,” Concord promoter Sudhir Vaid said.